author_facet Olafsdottir, T. A.
Lingnau, K.
Nagy, E.
Jonsdottir, I.
Olafsdottir, T. A.
Lingnau, K.
Nagy, E.
Jonsdottir, I.
author Olafsdottir, T. A.
Lingnau, K.
Nagy, E.
Jonsdottir, I.
spellingShingle Olafsdottir, T. A.
Lingnau, K.
Nagy, E.
Jonsdottir, I.
Scandinavian Journal of Immunology
IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
Immunology
General Medicine
author_sort olafsdottir, t. a.
spelling Olafsdottir, T. A. Lingnau, K. Nagy, E. Jonsdottir, I. 0300-9475 1365-3083 Wiley Immunology General Medicine http://dx.doi.org/10.1111/j.1365-3083.2008.02225.x <jats:title>Abstract</jats:title><jats:p>IC31<jats:sup>®</jats:sup> is a novel adjuvant which combines the immunostimulatory effects of an 11‐mer antibacterial peptide (KLKL<jats:sub>5</jats:sub>KLK) and a synthetic oligodeoxynucleotide (ODN1a) which is a Toll‐like receptor 9 agonist without containing cytosine phosphate guanine (CpG) motifs. The effects of IC31<jats:sup>®</jats:sup> on neonatal immune response to vaccination have not been reported. Neonatal mice were immunized once or twice with a <jats:italic>Streptococcus pneumoniae</jats:italic> serotype 1 polysaccharide conjugate containing Tetanus Toxoid (Pnc1‐TT) carrier protein, with or without IC31<jats:sup>®</jats:sup> or CpG‐ODN. IC31<jats:sup>®</jats:sup> significantly enhanced IgG1, IgG2a and IgG2b antibodies (Ab) to the serotype 1 polysaccharide. One dose of Pnc1‐TT and low dose IC31<jats:sup>®</jats:sup> elicited high Ab levels that protected the neonatal mice completely from bacteraemia and significantly reduced lung infection following i.n. challenge with serotype 1 pneumococcal strain. One‐sixth of an adult murine dose of IC31<jats:sup>®</jats:sup> was sufficient and optimal for induction of protective immunity in neonatal mice. Two doses of Pnc1‐TT with or without adjuvants protected the neonatal mice completely, but more rapid Ab response was observed when IC31<jats:sup>®</jats:sup> was given with the Pnc1‐TT. IC31<jats:sup>®</jats:sup> is a promising new adjuvant for neonatal vaccinations, rapidly enhancing protective humoral responses when combined with Pnc1‐TT.</jats:p> IC31<sup>®</sup>, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice Scandinavian Journal of Immunology
doi_str_mv 10.1111/j.1365-3083.2008.02225.x
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjEzNjUtMzA4My4yMDA4LjAyMjI1Lng
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjEzNjUtMzA4My4yMDA4LjAyMjI1Lng
institution DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
imprint Wiley, 2009
imprint_str_mv Wiley, 2009
issn 0300-9475
1365-3083
issn_str_mv 0300-9475
1365-3083
language English
mega_collection Wiley (CrossRef)
match_str olafsdottir2009ic31ratwocomponentnoveladjuvantmixedwithaconjugatevaccineenhancesprotectiveimmunityagainstpneumococcaldiseaseinneonatalmice
publishDateSort 2009
publisher Wiley
recordtype ai
record_format ai
series Scandinavian Journal of Immunology
source_id 49
title IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
title_unstemmed IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
title_full IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
title_fullStr IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
title_full_unstemmed IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
title_short IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
title_sort ic31<sup>®</sup>, a two‐component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice
topic Immunology
General Medicine
url http://dx.doi.org/10.1111/j.1365-3083.2008.02225.x
publishDate 2009
physical 194-202
description <jats:title>Abstract</jats:title><jats:p>IC31<jats:sup>®</jats:sup> is a novel adjuvant which combines the immunostimulatory effects of an 11‐mer antibacterial peptide (KLKL<jats:sub>5</jats:sub>KLK) and a synthetic oligodeoxynucleotide (ODN1a) which is a Toll‐like receptor 9 agonist without containing cytosine phosphate guanine (CpG) motifs. The effects of IC31<jats:sup>®</jats:sup> on neonatal immune response to vaccination have not been reported. Neonatal mice were immunized once or twice with a <jats:italic>Streptococcus pneumoniae</jats:italic> serotype 1 polysaccharide conjugate containing Tetanus Toxoid (Pnc1‐TT) carrier protein, with or without IC31<jats:sup>®</jats:sup> or CpG‐ODN. IC31<jats:sup>®</jats:sup> significantly enhanced IgG1, IgG2a and IgG2b antibodies (Ab) to the serotype 1 polysaccharide. One dose of Pnc1‐TT and low dose IC31<jats:sup>®</jats:sup> elicited high Ab levels that protected the neonatal mice completely from bacteraemia and significantly reduced lung infection following i.n. challenge with serotype 1 pneumococcal strain. One‐sixth of an adult murine dose of IC31<jats:sup>®</jats:sup> was sufficient and optimal for induction of protective immunity in neonatal mice. Two doses of Pnc1‐TT with or without adjuvants protected the neonatal mice completely, but more rapid Ab response was observed when IC31<jats:sup>®</jats:sup> was given with the Pnc1‐TT. IC31<jats:sup>®</jats:sup> is a promising new adjuvant for neonatal vaccinations, rapidly enhancing protective humoral responses when combined with Pnc1‐TT.</jats:p>
container_issue 3
container_start_page 194
container_title Scandinavian Journal of Immunology
container_volume 69
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792343598480490498
geogr_code not assigned
last_indexed 2024-03-01T16:54:14.32Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=IC31%C2%AE%2C+a+Two%E2%80%90Component+Novel+Adjuvant+Mixed+with+a+Conjugate+Vaccine+Enhances+Protective+Immunity+against+Pneumococcal+Disease+in+Neonatal+Mice&rft.date=2009-03-01&genre=article&issn=1365-3083&volume=69&issue=3&spage=194&epage=202&pages=194-202&jtitle=Scandinavian+Journal+of+Immunology&atitle=IC31%3Csup%3E%C2%AE%3C%2Fsup%3E%2C+a+Two%E2%80%90Component+Novel+Adjuvant+Mixed+with+a+Conjugate+Vaccine+Enhances+Protective+Immunity+against+Pneumococcal+Disease+in+Neonatal+Mice&aulast=Jonsdottir&aufirst=I.&rft_id=info%3Adoi%2F10.1111%2Fj.1365-3083.2008.02225.x&rft.language%5B0%5D=eng
SOLR
_version_ 1792343598480490498
author Olafsdottir, T. A., Lingnau, K., Nagy, E., Jonsdottir, I.
author_facet Olafsdottir, T. A., Lingnau, K., Nagy, E., Jonsdottir, I., Olafsdottir, T. A., Lingnau, K., Nagy, E., Jonsdottir, I.
author_sort olafsdottir, t. a.
container_issue 3
container_start_page 194
container_title Scandinavian Journal of Immunology
container_volume 69
description <jats:title>Abstract</jats:title><jats:p>IC31<jats:sup>®</jats:sup> is a novel adjuvant which combines the immunostimulatory effects of an 11‐mer antibacterial peptide (KLKL<jats:sub>5</jats:sub>KLK) and a synthetic oligodeoxynucleotide (ODN1a) which is a Toll‐like receptor 9 agonist without containing cytosine phosphate guanine (CpG) motifs. The effects of IC31<jats:sup>®</jats:sup> on neonatal immune response to vaccination have not been reported. Neonatal mice were immunized once or twice with a <jats:italic>Streptococcus pneumoniae</jats:italic> serotype 1 polysaccharide conjugate containing Tetanus Toxoid (Pnc1‐TT) carrier protein, with or without IC31<jats:sup>®</jats:sup> or CpG‐ODN. IC31<jats:sup>®</jats:sup> significantly enhanced IgG1, IgG2a and IgG2b antibodies (Ab) to the serotype 1 polysaccharide. One dose of Pnc1‐TT and low dose IC31<jats:sup>®</jats:sup> elicited high Ab levels that protected the neonatal mice completely from bacteraemia and significantly reduced lung infection following i.n. challenge with serotype 1 pneumococcal strain. One‐sixth of an adult murine dose of IC31<jats:sup>®</jats:sup> was sufficient and optimal for induction of protective immunity in neonatal mice. Two doses of Pnc1‐TT with or without adjuvants protected the neonatal mice completely, but more rapid Ab response was observed when IC31<jats:sup>®</jats:sup> was given with the Pnc1‐TT. IC31<jats:sup>®</jats:sup> is a promising new adjuvant for neonatal vaccinations, rapidly enhancing protective humoral responses when combined with Pnc1‐TT.</jats:p>
doi_str_mv 10.1111/j.1365-3083.2008.02225.x
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjEzNjUtMzA4My4yMDA4LjAyMjI1Lng
imprint Wiley, 2009
imprint_str_mv Wiley, 2009
institution DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161
issn 0300-9475, 1365-3083
issn_str_mv 0300-9475, 1365-3083
language English
last_indexed 2024-03-01T16:54:14.32Z
match_str olafsdottir2009ic31ratwocomponentnoveladjuvantmixedwithaconjugatevaccineenhancesprotectiveimmunityagainstpneumococcaldiseaseinneonatalmice
mega_collection Wiley (CrossRef)
physical 194-202
publishDate 2009
publishDateSort 2009
publisher Wiley
record_format ai
recordtype ai
series Scandinavian Journal of Immunology
source_id 49
spelling Olafsdottir, T. A. Lingnau, K. Nagy, E. Jonsdottir, I. 0300-9475 1365-3083 Wiley Immunology General Medicine http://dx.doi.org/10.1111/j.1365-3083.2008.02225.x <jats:title>Abstract</jats:title><jats:p>IC31<jats:sup>®</jats:sup> is a novel adjuvant which combines the immunostimulatory effects of an 11‐mer antibacterial peptide (KLKL<jats:sub>5</jats:sub>KLK) and a synthetic oligodeoxynucleotide (ODN1a) which is a Toll‐like receptor 9 agonist without containing cytosine phosphate guanine (CpG) motifs. The effects of IC31<jats:sup>®</jats:sup> on neonatal immune response to vaccination have not been reported. Neonatal mice were immunized once or twice with a <jats:italic>Streptococcus pneumoniae</jats:italic> serotype 1 polysaccharide conjugate containing Tetanus Toxoid (Pnc1‐TT) carrier protein, with or without IC31<jats:sup>®</jats:sup> or CpG‐ODN. IC31<jats:sup>®</jats:sup> significantly enhanced IgG1, IgG2a and IgG2b antibodies (Ab) to the serotype 1 polysaccharide. One dose of Pnc1‐TT and low dose IC31<jats:sup>®</jats:sup> elicited high Ab levels that protected the neonatal mice completely from bacteraemia and significantly reduced lung infection following i.n. challenge with serotype 1 pneumococcal strain. One‐sixth of an adult murine dose of IC31<jats:sup>®</jats:sup> was sufficient and optimal for induction of protective immunity in neonatal mice. Two doses of Pnc1‐TT with or without adjuvants protected the neonatal mice completely, but more rapid Ab response was observed when IC31<jats:sup>®</jats:sup> was given with the Pnc1‐TT. IC31<jats:sup>®</jats:sup> is a promising new adjuvant for neonatal vaccinations, rapidly enhancing protective humoral responses when combined with Pnc1‐TT.</jats:p> IC31<sup>®</sup>, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice Scandinavian Journal of Immunology
spellingShingle Olafsdottir, T. A., Lingnau, K., Nagy, E., Jonsdottir, I., Scandinavian Journal of Immunology, IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice, Immunology, General Medicine
title IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
title_full IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
title_fullStr IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
title_full_unstemmed IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
title_short IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
title_sort ic31<sup>®</sup>, a two‐component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice
title_unstemmed IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
topic Immunology, General Medicine
url http://dx.doi.org/10.1111/j.1365-3083.2008.02225.x